Ivor Elrifi bought $667k of TLSA
Chief Executive Officer at Tiziana Life Sciences Ltd. 667,000 shares at an average of $1.00, traded Aug 3, 2026, filed Aug 5, 2026.
Score components
- +25RoleCEO
- +20Trade size$667k at market
- +3Relative to holdingsHoldings up 18%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-085710, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | POpen-market purchase COMMON STOCKindirect: By trust | +667,000 | $1.00 | $667k | 4,472,261 | Aug 5, 2026 |
Related signals
Other insiders at Tiziana Life Sciences Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | TLSAbuy Tiziana Life Sciences Ltd | Gabriele M Cerrone director, owner | $17k 15,000 shares | +0% | |
| 39Weak | Tiziana Life Sciences Ltd | Gabriele M Cerrone director, owner | $42k 42,357 shares | +0% | |
| 55Moderate | Tiziana Life Sciences Ltd | Ivor Elrifi Chief Executive Officer | $319k 321,423 shares | +7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.